Dr Xin (Cindy) Zhang received her PhD in 2021 and was awarded the 2021 Mollie Holman Medal for doctoral thesis excellence by Monash University for studies on the glucagon-like peptide-1 receptor (GLP-1R) in the lab of Profs. Patrick Sexton and Denise Wootten. She was then recruited as a Postdoctoral Fellow in the same laboratory on projects aligned to the Australian Research Council (ARC) Centre for Cryo-EM of Membrane Proteins (CCeMMP), and was recently awarded an ARC Discovery Early Career Researcher Award (DECRA) fellowship (2023-2026). Her research program incorporates cell biology, biochemistry, structural biology (in particular cryo-EM) and pharmacology to gain molecular insights into G protein-coupled receptors (GPCRs). Her particular interest is in the structure-function relationships of glucagon family GPCRs to understand how diverse ligands bind to and activate these receptors, which are clinically important drug targets for the treatment of type II diabetes and obesity.

Liz Johnstone obtained her PhD in Pharmacology from the University of Western Australia (UWA) in 2016. Since then she has continued her research into the molecular pharmacology of receptors at the Harry Perkins Institute of Medical Research/UWA Centre for Medical Research. In 2017, she spent a year working part time as Senior Project Officer for Accelerating Australia, a consortium dedicated to promoting biomedical innovation and entrepreneurship. In 2021 she was appointed as a Pharmacology Lecturer in the UWA School of Biomedical Sciences, while she continues her research at the Harry Perkins Institute of Medical Research. Liz is a currently a Member Elected Director of the ASCEPT Board, a member of the IUPHAR Early Career Committee Member and an Elected Council Member of the Endocrine Society of Australia.

After completing a Master of Science in Clinical Epidemiology followed by a Doctor of Pharmacy at the University of Sydney, Dr. Fujita has been working as a Postdoctoral Research Fellow at the Kolling Institute Ageing and Pharmacology Laboratory since 2020. His unique combination of expertise in clinical pharmacology, epidemiology, and big data analytics, along with his previous experience in developing web applications, positions him to lead several innovative projects. His research focuses on improving medication management for older adults, particularly through deprescribing, frailty assessment, and monitoring the quality of care. Dr. Fujita, who previously worked as a pharmacist in Japan, currently serves as the co-lead of the working group on guidelines and indicators within a pharmacy practice research group in Europe, Pharmaceutical Care Network Europe (PCNE). He is also an executive committee member of the Social and Administrative Pharmacy Section in the International Pharmaceutical Federation (FIP) and the chairperson of a research committee within the Association of Pharmacist Home Visiting Service in Japan (J-HOP)

Dr Justin Turner has extensive experience providing patient care and leading research across aged care, primary care, tertiary care and academia in Australia, Europe and North America. His research seeks to answer the question, “How can we optimise medication use in older adults?” Dr Turner’s research is driven by a passion for improving medication management and reducing medication-related harm. Dr. Turner completed his Master of Clinical Pharmacy at the University of South Australia and his PhD at Monash University. He then undertook a Postdoctoral Fellowship at the University of Montreal, where he focused on designing, implementing, and evaluating evidence-based deprescribing interventions at a population level. Notable achievements during his time in Canada include conducting the first nationwide survey on deprescribing, leading a randomized controlled trial on opioid reduction, and instigating policy changes to incentivize pharmacists to deprescribe. His leadership in the SaferMedsNL initiative educated and engaged residents of Newfoundland and Labrador about the risks of medication-related harm and the importance of deprescribing. As an inaugural member of the Australian Deprescribing Network (ADeN) and Co-Director of the Canadian Appropriate Medication Use and Deprescribing Network (CADeN), Dr. Turner has been at the forefront of deprescribing internationally. Dr Turner has been an investigator on successful grants and scholarships totalling over $10 million and received awards for research excellence from both the Canadian Geriatrics Society and the American Geriatrics Society. Dr. Turner's current research seeks to adapt international best practices in patient-led deprescribing to the contexts of Australia, Canada, and the United States. His work continues to influence health policies and clinical practice, leading to safer and more effective medication use for older adults globally.